Wells Fargo & Company Lowers Soleno Therapeutics (NASDAQ:SLNO) Price Target to $110.00

Soleno Therapeutics (NASDAQ:SLNO) had its target price lowered by stock analysts at Wells Fargo & Company from $114.00 to $110.00 in a report issued on Friday,Benzinga reports. The firm currently has an “overweight” rating on the stock. Wells Fargo & Company‘s target price suggests a potential upside of 181.55% from the stock’s current price.

SLNO has been the topic of several other research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Soleno Therapeutics in a research note on Thursday, January 22nd. HC Wainwright reissued a “buy” rating and set a $120.00 price objective (up from $110.00) on shares of Soleno Therapeutics in a report on Tuesday, January 20th. Robert W. Baird set a $107.00 price target on shares of Soleno Therapeutics in a research report on Tuesday, January 13th. TD Cowen dropped their price target on shares of Soleno Therapeutics from $120.00 to $85.00 and set a “buy” rating for the company in a research note on Thursday. Finally, Zacks Research cut shares of Soleno Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, February 3rd. One investment analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $108.38.

Soleno Therapeutics Price Performance

SLNO opened at $39.07 on Friday. The company has a debt-to-equity ratio of 0.10, a current ratio of 16.08 and a quick ratio of 15.88. The stock has a market capitalization of $2.02 billion, a P/E ratio of 169.88 and a beta of -3.16. The company’s 50 day simple moving average is $42.63 and its 200-day simple moving average is $53.33. Soleno Therapeutics has a one year low of $32.63 and a one year high of $90.32.

Soleno Therapeutics (NASDAQ:SLNO) last posted its quarterly earnings data on Wednesday, February 25th. The company reported $0.80 earnings per share for the quarter, topping the consensus estimate of $0.64 by $0.16. The company had revenue of $91.73 million during the quarter, compared to the consensus estimate of $88.55 million. Sell-side analysts anticipate that Soleno Therapeutics will post -3.72 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Soleno Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Raymond James Financial Inc. bought a new stake in shares of Soleno Therapeutics in the 2nd quarter valued at $25,000. Danske Bank A S bought a new position in Soleno Therapeutics during the third quarter worth about $27,000. Global Retirement Partners LLC grew its stake in Soleno Therapeutics by 519.0% in the fourth quarter. Global Retirement Partners LLC now owns 619 shares of the company’s stock valued at $29,000 after acquiring an additional 519 shares during the period. Aster Capital Management DIFC Ltd acquired a new stake in shares of Soleno Therapeutics during the third quarter worth about $37,000. Finally, Nisa Investment Advisors LLC lifted its holdings in shares of Soleno Therapeutics by 287.8% during the 2nd quarter. Nisa Investment Advisors LLC now owns 539 shares of the company’s stock valued at $45,000 after purchasing an additional 400 shares in the last quarter. 97.42% of the stock is owned by institutional investors.

Key Soleno Therapeutics News

Here are the key news stories impacting Soleno Therapeutics this week:

• Positive Sentiment: Earnings beat and profitability: Soleno reported Q4 2025 EPS of $0.80 (vs. $0.64 consensus) and revenue of $91.73M (vs. $88.55M), and management highlighted achieving profitability — the core reason investors are bidding the stock up. Soleno Therapeutics, Inc. Q4 2025 Earnings Call Summary
• Neutral Sentiment: Full earnings/transcript availability: Multiple transcripts and call write-ups (Seeking Alpha, Yahoo) give investors detailed color on guidance, margins and cash flow — useful for conviction but not immediate catalysts. Q4 2025 Earnings Call Transcript Q4 2025 Earnings Call Highlights
• Neutral Sentiment: Wells Fargo cut its price target slightly from $114 to $110 but kept an Overweight rating — this is a modest headwind but still signals strong upside from analysts. Wells Fargo price-target note
• Negative Sentiment: TD Cowen substantially lowered its target (from $120 to $85) despite maintaining a Buy rating — the larger cut adds downward pressure to headline analyst sentiment and may temper the rally. TD Cowen price-target change
• Negative Sentiment: Near-term volatility / profit-taking explained: Coverage and commentary note a sharp intraday decline (reported as ~10.8% in one write-up) after the earnings run-up — investors appear to be re‑rating the name on guidance details, forward EPS expectations, and valuation. Why SLNO Stock Is Down 10.80%

About Soleno Therapeutics

Soleno Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development and commercialization of therapies for rare and orphan diseases. Headquartered in Redwood City, California, Soleno leverages a precision medicine approach to identify and advance small‐molecule treatments that address underlying genetic and metabolic dysfunctions. The company’s scientific strategy centers on repurposing and reformulating existing compounds to maximize therapeutic benefit in underserved patient populations.

The company’s lead candidate, diazoxide choline controlled release (DCCR), is being investigated for the treatment of Prader-Willi syndrome (PWS), a complex neurodevelopmental disorder characterized by insatiable appetite, hormonal imbalances and behavioral challenges.